Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03248492 Not yet recruiting - Breast Cancer Clinical Trials

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Start date: August 2017
Phase: Phase 2
Study type: Interventional

Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

NCT ID: NCT03238976 Not yet recruiting - Breast Cancer Clinical Trials

Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy

Start date: October 2017
Phase: N/A
Study type: Interventional

Patients will be randomly assigned to one of two groups: the group exposed to NS, or the standard care group exposed to supportive dialogue. Patients assigned to the former group will be exposed to continuous NS throughout the CNB procedure.

NCT ID: NCT03238053 Not yet recruiting - Breast Cancer Clinical Trials

Laser Treatment of Genito-urinary Syndrome in Women

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Women with genitourinary syndrome of menopause, with breast or endometrial cancer are randomized to either laser treatment og sham treatment for 3 months. The randomization is stratified for estrogen treatment. The effect is evaluated by questionnaire, histology and microbiology swaps

NCT ID: NCT03237572 Not yet recruiting - Breast Cancer Clinical Trials

Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer

Breast-48
Start date: August 25, 2017
Phase: Phase 1
Study type: Interventional

This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants will be randomized to receive their first dose of pembrolizumab before HIFU.

NCT ID: NCT03232541 Not yet recruiting - Breast Cancer Clinical Trials

The Effects of Acupuncture and the Therapist´s Communication on Chemo-therapy Induced Nausea and Vomiting

Start date: July 28, 2017
Phase: N/A
Study type: Interventional

Background: Nausea and vomiting (emesis) is a common known problem for patients with cancer who are undergoing chemotherapy. Emesis affects both the patient´s quality of life and induces high costs within the health-care system. Acupuncture is an upcoming treatment for emesis, despite lacking evidence for effects beside non-specific effects since few credibly sham-controlled studies previously have been conducted. The therapist's care and communication during the needling sessions may induce non-specific effects, potentially driven by the patient's expectations. It is not known if the type of communication, in terms of how positive the therapist communicates regarding expected effects, affects the effect of acupuncture for emesis. Aims: The aim of this study is to investigate if chemotherapy-induced nausea, vomiting, and quality of life differ between patients who receive a) standard care including antiemetics, b) standard care plus sham acupuncture or c) standard treatment plus genuine acupuncture. The aim is also to investigate if chemotherapy-induced nausea, vomiting, and quality of life differ between patients who receive the above mentioned standard care, sham acupuncture, or genuine acupuncture by a therapist who emphasizes the positive expected outcomes of the treatment, compared to a therapist who communicates neutral regarding the outcomes. Procedure: The eligible patients will be randomized to A) standard care, including antiemetics or to B) standard treatment plus sham acupuncture or C) standard treatment plus genuine acupuncture. Within the three groups, the patients are randomized to receive either neutral or positive communication with the therapist during the treatment. Outcome measures: Nausea and vomiting are documented in questionnaires and in a diary, measured with Visual Analogue Scales. Well-being, activity level and quality of life are measured with questionnaires.

NCT ID: NCT03227328 Not yet recruiting - Breast Cancer Clinical Trials

CHemo-ENDOcrine Therapy in Advanced Breast Cancer

CHENDO
Start date: July 2017
Phase: Phase 3
Study type: Interventional

Prospective, open label, multicenter, randomized phase III study, comparing two strategies as first chemotherapy-based treatment for locally advanced or metastatic luminal breast cancer. - Arm A: concomitant chemotherapy plus an aromatase inhibitor (AI); the AI must continue until disease progression or toxicity or patient refusal; chemotherapy may be stopped after achievement of maximum response (generally after at least about 3-6 months of treatment) or in case of toxicity or patient refusal. - Arm B: chemotherapy followed by an AI at the time of progression to chemotherapy (if an endocrine therapy is deemed indicated by the treating physician) or as maintenance therapy after achieving maximum response to chemotherapy (generally after at least about 3-6 months of treatment) or after stopping chemotherapy for toxicity or patient refusal.

NCT ID: NCT03222856 Not yet recruiting - Breast Cancer Clinical Trials

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

KELLY
Start date: October 1, 2017
Phase: Phase 2
Study type: Interventional

This a multicenter, open-label, phase II clinical trial to assess the efficacy of pembrolizumab in combination with eribulin in female patients older than 18 years old with hormone receptor-(HR)positive/HER2-negative metastatic breast cancer (MBC) previously treated with at least one, but not more than two, prior chemotherapeutic regimens for treatment of locally recurrent and/or metastatic disease. Prior therapy must have included an anthracycline and a taxane and prior anti-hormonal therapy is mandatory. The number of patients to be included is 44 patients at 11 sites. All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle.

NCT ID: NCT03219476 Not yet recruiting - Breast Cancer Clinical Trials

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.

NCT ID: NCT03211572 Not yet recruiting - Breast Cancer Clinical Trials

The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers

OTT 17-01
Start date: August 2017
Phase: Phase 2
Study type: Interventional

Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers

NCT ID: NCT03210311 Not yet recruiting - Breast Cancer Clinical Trials

Pre-existing Factors, Early Detection and Early Treatment of Breast Cancer Related Lymphedema

DEARLY
Start date: September 4, 2017
Phase: Phase 3
Study type: Interventional

Breast-cancer related lymphoedema (BCRL) is a common phenomenon. Early diagnosis and treatment is very important to alter the normal progression of this disease. A threshold (>= 3% volume change) that recognizes subclinical lymphedema is promoted. When the lymphedema is diagnosed late, options for treatment are diminished as fibrous tissue is formed. Preoperative investigation with near-infrared fluorescence lymphography can show an abnormality. Even if a linear transport is visualized, velocity of the transport can be diminished or a different pathway than normal can be visualized. Such an extensive evaluation has not been performed yet. This lymphofluoroscopy gives an opportunity to detect lymphedema earlier than clinically visible (subclinical). The investigators hypothesize that the evolution of lymphedema can be altered if treatment is started in the subclinical phase.